Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.46 |
| ▸ | SLC6A12 | P48065 | 5/20 | 0.44 |
| ▸ | SLC6A11 | P48066 | 5/20 | 0.44 |
| ▸ | SLC6A13 | Q9NSD5 | 5/20 | 0.44 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL7803541 | 1.00 | ANPEP (0.46) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL200896 | 0.91 | ANPEP (0.52) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL229034 | 0.91 | ANPEP (0.52) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL200897 | 0.91 | ANPEP (0.52) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL2993122 | 0.89 | ANPEP (0.50) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL2993124 | 0.89 | ANPEP (0.50) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL4276196 | 0.89 | ANPEP (0.50) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL3542706 | 0.85 | ANPEP (0.47) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL3542704 | 0.85 | ANPEP (0.47) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL24483431 | 0.79 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725241-A4 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-03-25 | — | — | EP | disclosed |
| US-20070185088-A1 | M3 muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1725241-A1 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | disclosed |
| EP-1119563-B1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2006-02-01 | — | — | EP | disclosed |
| EP-1119562-B1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005094835-A1 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
| US-6855717-B2 | Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors | SMITHKLINE BEECHAM, PLC (GB) | 2005-02-15 | — | — | US | disclosed |
| US-20030191314-A1 | Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors | SMITHKLINE BEECHAM, P.L.C. | 2003-10-09 | — | — | US | disclosed |
| US-20030158222-A1 | 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents) | SMITHKLINE BEECHAM P.L.C. | 2003-08-21 | — | — | US | disclosed |
| US-6605607-B1 | Antihypertensives; hyperprolactinaemia related conditions; certain central nervous system disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-08-12 | — | — | US | disclosed |
| US-6521638-B1 | Such as 2-(2-(1-(4-(3-(3-methanesulfonyl)phenylpropenoyl)-amino)cyclohexyl)ethyl) -2,3-dihydro-1H-isoindole; amidation of amine and carbonyl halide | SMITHKLINE BEECHAM P.L.C. (DE) | 2003-02-18 | — | — | US | disclosed |
| EP-1086095-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2002-10-23 | — | — | EP | disclosed |
| US-6465485-B1 | SUCH AS 7-CYANO-2-(2-(1-(4-(2-INDOLYL)CARBOXAMIDO)CYCLO-HEXYL)ETHYL)-1,2,3,4 -TETRAHYDROISOQUINOLINE; ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-15 | — | — | US | disclosed |
| US-6414154-B1 | TREATING PSYCHOTIC CONDITIONS OR SUBSTANCE ABUSE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-02 | — | — | US | disclosed |
| US-6358974-B1 | USED AS AS MODULATORS OF DOPAMINE D.SUB.3 RECEPTORS, IN THERAPY AS ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191314-A1 | Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors | OPRD1, HTR3C, DRD3 | ANPEP 3349/4885ENPEP 4078/4885SLC6A12 3249/4885 |
| US-20030158222-A1 | 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents) | OPRD1, DRD3, OPRM1 | ANPEP 4133/4885ENPEP 4633/4885SLC6A12 2127/4885 |
| US-20070185088-A1 | M3 muscarinic acetylchoine receptor antagonists | CHRM3, CHRM2, CHRM5 | ANPEP 2355/4885ENPEP 1174/4885SLC6A12 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.